


Yago Pico de Coaña

The following relationships exist related to this presentation:

No Relationships to Disclose


Ipilimumab enhances T cell activation while decreasing the suppressive potential of MDSCs

Yago Pico de Coaña, PhD
Department of Oncology-Pathology
Karolinska Institutet
Stockholm, Sweden



Attenuated or Terminated Proliferation


Unrestrained Proliferation




Investigates	CD4 T cells	CD8 T cells	Tregs	MDSC/MΦs	DC/MDSC	Tcell Function	Arg	Ox stress myeloid	Ox stress lymphoid	NK cells	Mono 1	Mono 2
FITC	CCR4	CCR5	FoxP3	CD68	CD11c	CD3	CD68	DCFDA	DCFDA	DNAM-1	CD80	DC-Sign
PE	CCR7	CCR7	ICOS	HLA-DR	HLA-DR	TCRzeta	HLA-DR	HLA-DR	CD4	NKp30/ NKp46	HLA-DR	HLA-DR
PE-Alf610	CD8	CD4	CD4		CD4							
PerCP-Cy5.5	CD28	CD28	CD28	CD3/CD19	CD3/CD19	CD4	iNOS	CD3/CD19	CD28	HLA-DR	CD14	CD14
PE-Cy7	CD3	CD3		CD15	CD15	CD56	CD3	CD11c	CD3	CD56	PD1L	CD137
APC	CD45RA	CD45RA	CD127	CD33	CD123	FasL (CD95)	CD33	CD33	CD127	NKG2D		
APC-Cy7	CD69	CD69	CD8	CD11b	CD11b	CD8	CD11b	CD11b	CD8	CD69		
PB	CXCR3	CXCR3	CD25	CD14	CD14	PD1	CD14	CD14	CD25	CD16	CD16	
PO/aqua DCM	DCM	DCM	DCM	DCM	DCM	DCM	Arg	DCM	DCM	CD3/DCM	DCM	DCM


43 Stage IV melanoma patients:

- 8 Stable disease
- 10 Partial responders (23% RR)
- Adverse events in 11 patients (Gr3-4)




Decreased T_{reg} population










CD4+ ICOS+












CD14⁻




(A) Non-treated



(B) Treated, non-responder



(C) Treated, responder





■ Physicians

- Johan Hansson
- Giuseppe Masucci
- Maria Wolodarski
- Rolf Kiessling

Research Nurses

- Karl-Johan Ekdahl
- Mette Wallin


■ Bench

- Giusy Gentilcore
- Maria Nyström
- Ulrika Edbäck
- Yuya Yoshimoto
- Sara Karlberg
- Isabel Poschke
- Rolf Kiessling



*Knut and Alice
Wallenberg
Foundation*

In cis effect



In trans effects:

